Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 47Leukemia 14Myelodysplastic Syndromes 12Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Leukemia, Biphenotypic, Acute 9Recurrence 8Leukemia, Lymphocytic, Chronic, B-Cell 8Blast Crisis 7Lymphoma, Mantle-Cell 6Leukemia, Hairy Cell 6Leukemia, Monocytic, Acute 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Waldenstrom Macroglobulinemia 3Neoplasm, Residual 3Myeloproliferative Disorders 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myelomonocytic, Chronic 3Burkitt Lymphoma 3Sarcoma, Myeloid 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Erythroblastic, Acute 2Graft vs Host Disease 2Thrombocythemia, Essential 1Targeted Therapy 1

Interventions

rozanolixizumab 10zilucoplan 8efgartigimod alfa 8Rituximab 7Cyclophosphamide 7telitacicept 6fludarabine 6eculizumab 5Prednisone 5ravulizumab 4Pyridostigmine Bromide 4Immunoglobulins, Intravenous 4Hizentra 4Tacrolimus 3Mycophenolic Acid 3HBM9161 3Amifampridine 3thymoglobulin 2inebilizumab 2Prednisolone 2Exercise 2tofacitinib 1tocilizumab 1talquetamab 1satralizumab 1sargramostim 1rhoA GTP-Binding Protein 1remibrutinib 1prednylidene 1iscalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Myasthenia Gravis × Cladribine × Clear all
NCT06463587 2026-05-22

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 3 Recruiting
264 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡